SECTION 2
Assessing the feasibility of a study’s design before it starts can mitigate many of the risks unique to neuroscience trials. We work with sponsors to deploy precision techniques in developing psychiatric and neurological treatments. It’s a nascent effort, but we see progress. Digital biomarkers could boost development efficiency and commercial viability for sponsors developing neuroscience treatments.
Contributing Experts
Stay current with novel thinking and actionable insights from our experts.
At Parexel, we advise sponsors on strategies to accelerate development timelines and effective ways to support approval and access to new neuroscience treatments. Sponsors can take calculated risks in this fast-evolving scientific and regulatory environment, such as utilizing novel biomarkers and endpoints, innovative trial designs, patient-guided feasibility testing, a bespoke regulatory strategy, and real-world evidence. We help them mitigate risks with expertise gained from experience.
In the past five years, our neuroscience-focused team of patient advocates, clinicians, scientists, statisticians, and former regulators has partnered with sponsors for more than 600 clinical and consulting projects, enrolling 47,000 patients.